Coherus Oncology, Inc. CHRS
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2014 · data as of November 13, 2026
Coherus Oncology, Inc. (CHRS) is a healthcare company listed in the US with a market value of about $81M. In the twelve months to September 30, 2026 it had revenue of $54M and net income of -$136M, a net margin of -253.4%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -264%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 86% below the current price.
About Coherus Oncology
Coherus Oncology is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2014. Revenue went from $31M in 2014 to $26M in 2024, a decline of about 1.6% a year. It was profitable in 4 of the last 10 years in our data. Its share count rose by 51% over three years (dilution for shareholders).
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54M | — | $26M | $257M | $211M | $327M | $476M | $356M | $0 | $2M | $190M |
| Net income | -$136M | $168M | $29M | -$238M | -$292M | -$287M | $132M | $90M | -$209M | -$238M | -$127M |
| Free cash flow | — | -$609M | -$248M | -$175M | -$243M | -$39M | $147M | $27M | -$160M | -$205M | -$259M |
| EPS (diluted) | $-1.00 | $1.43 | $0.25 | $-2.53 | $-3.76 | $-3.81 | $1.62 | $1.23 | $-3.22 | $-4.48 | $-2.96 |
| Net margin | -253.4% | — | 108.0% | -92.5% | -138.2% | -87.9% | 27.8% | 25.2% | — | -15306.6% | -67.0% |
| ROIC | — | -281.7% | — | — | — | -246.1% | 52.1% | 88.7% | — | -760.2% | -446.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Coherus Oncology stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 86% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Coherus Oncology pay a dividend?
Not currently.
Is Coherus Oncology a good stock to buy?
We do not give buy or sell advice. Coherus Oncology scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.